**PATENT** 

Docket No.: 176/60807 (6-11406-955)

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

			١.	
Applicants	:	Thomas J. Guttuso, Jr.	)	Examiner:
Serial No.	:	Continuation of 09/879,390	)	To Be Assigned
			)	Art Unit:
Cnfrm. No.	:	To Be Assigned	)	To Be Assigned
Filed	:	Herewith	)	
For	:	METHOD OF TREATING SYMPTOMS OF HORMONAL VARIATION, INCLUDING HOT FLASHES, USING TACHYKININ RECEPTOR ANTAGONIST	•	

# INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.97-1.98

Mail Stop: Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR §§ 1.97-1.98, applicant hereby brings to the attention of the United States Patent and Trademark Office, the enclosed references listed on the attached PTO-1449 form.

Pursuant to 37 CFR § 1.98(d), the references identified on the attached PTO-1449 form are not provided, because these references either were previously cited by or submitted to the PTO in parent U.S. Patent Application Serial No. 09/879,390, filed June 12, 2001, of which this application claims priority under 35 USC § 120.

Respectfully submitted,

Date: June 27, 2003

Edwin V. Merkel

Registration No. 40,087

NIXON PEABODY LLP Clinton Square, P.O. Box 31051 Rochester, New York 14603-1051

Telephone: (585) 263-1128 Facsimile: (585) 263-1600

R695020.1

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SERIAL NO.				
INFORMATION DISCLOSURE	176/60807 (6-11405-955)	CON of 09/879,390				
STATEMENT BY APPLICANT	APPLICANT					
(use converse charts if managemy)	Thomas J. Guttuso, Jr.					
(use several sheets if necessary)	FILING DATE	GROUP ART UNIT				
(PTO-1449)	Herewith					

#### U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE
	1	5,744,156		De Lacharriere et al.			

### FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE
2	WO 99/09987	03/04/99	WIPO			
3	WO 98/43639	10/08/98	WIPO			
4	WO 96/24353	08/15/96	WIPO			

### OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

}	5	Hay, "Chronic Obstructive Pulmonary Disease: Emerging Therapies," Current Opinion in Chemical Biology 4:412-419					
		(2000)					
	6	Abraham et al., "Cancer Chemotherapy and Radiation Induced Emesis (CRIE): Current and Future Therapeutic Approaches,"					
		Indian Journal of Pharmacology 32:256-268 (2000)					
	7	Von Sprecher et al., "Neurokinin Antagonists as Potential Therapies for Inflammation and Rheumatoid Arthritis,"					
		<u>Idrugs</u> 1(1):73-91 (1998)					
	8	Rance et al., "Hypertrophy and Increased Gene Expression of Neurons Containing Neurokinin-B and Substance-P Messenger					
	1	Ribonucleic Acids in the Hypothalami of Postmenopausal Women," Endocrinology 128(5):2239-2247 (1991)					
	9	Casper et al., "Menopausal Flushes: A Neuroendocrine Link with Pulsatile Luteinizing Hormone Secretion,"					
1	1	<u>Science</u> 205:823-825 (1979)					
	10	Norheim et al., "Tachykinins in Carcinoid Tumors: Their Use as a Tumor Marker and Possible Role in the Carcinoid Flush,"					
		Journal of Clinical Endocrinology and Metabolism 63(3):605-612 (1986)					
	11	Conlon et al., "Circulating Tachykinins (Substance P, Neurokinin A, Neuropeptide K) and the Carcinoid Flush,"					
		Scand. J. Gastroenterol. 22: 97-105 (1986)					
	12	Öberg et al., "The Effects of Octreotide on Basal and Stimulated Hormone Levels in Patients with Carcinoid Syndrome,"					
	1	Journal of Clinical Endocrinology and Metabolism 68(4):796-800 (1989)					
XAMINER		DATE CONSIDERED					

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

						<u>.</u>		SI	heet 2 of 2
U.S. DEPARTME PATENT AND TR			ATTY. DC	OCKET NO.				AL NO.	
INFORMATIO			176/60807	(6-11405-955)			CON	of 09/879,390	
STATEMENT	STATEMENT BY APPLICANT			NT					
(use several sheets if necessary)			Thomas J.	. Guttuso, Jr.					
	(PTO-1449)			ATE			GROU	UP ART UNIT	
\ ·	J. 1442 ,		Herewith			**************************************		**************************************	·
				U.S. PATEN7	I DOCUMENTS				
EXAMINER INITIAL	· · · · · · · · · · · · · · · · · · ·		1	DATE	NAME	CLA	ss	SUBCLASS	FILING DATE IF APPRO- PRIATE
						-		<b></b>	
						-			
		<del></del>				-			
		-	-			-			
		-	-			-		<del> </del>	
		<del> </del>	-			-		<del>                    -       -  </del>	
1		<u> </u>				<u> </u>		<u></u>	
				FOREIGN PATE	ENT DOCUMENTS				
		DOCUN		DATE	COUNTRY		LASS	SUBCLASS	TRANS- LATION IF APPRO-
ļ <u>-</u>		<del></del>		<del></del> '	-				PRIATE
	·	-				-		+	
		-			<del> </del>				<del> </del>
		<u></u>							<u></u>
		OTHE	R DOCUME	NTS (including Au	uthor, Title, Date, Pertinent	Pages, Etc	2.)		
	13	Balks et al., "	Effect of a L	ong-Acting Somator	statin Analogue (Octreotide) or	n Circulati	ng Tachy	ykinins and the	
		Pentagastrin-I	nduced Carci	noid Flush," Eur. J	J. Clin. Pharmacol. 36:133-13	7 (1989)	<del></del>		
	14	<del>†</del>			nd Plasma Substance P Concer		uring Infi	usion of Synthetic 5	Substance
		P in Normal N	Man," Scand.	J. Gastroenterol. 2	.1: 498-502 (1985)				
	!								
EXAMINER				·	DATE CONSI	DERED			
EVAMINER: Initi	int if citat	-in- considered	hather or t	at sitution is in con	formance with MPEP 609; Dr	line th			on and
				munication to applic		aw mic un	Ougii Cia	ation it not in come	Thance and

								•	Sheet 1 of 2
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. I	OCKET NO.			SERL	AL NO.	incet 1 of 2
			176/6080	7 (6-11405-955)			CON	of 09/879,390	
INFORMAT STATEMEN			APPLICA	ANT			•		<del></del>
(use several	chaste if	· nacessam/)	Thomas	J. Guttuso, Jr.					
	TO-1449	•	FILING	DATE			GROU	JP ART UNIT	
(1	10-14-2	<i>'</i>	Herewith	1					
				U.S. PATE	NT DOCUMENTS				
EXAMINER INITIAL		DOCUMENT NUMBER		DATE	NAME	CLA	ASS	SUBCLASS	FILING DATE IF APPRO- PRIATE
	1	5,744,156			De Lacharriere et al.	al.			
						<u></u>			
				FOREIGN PA	TENT DOCUMENTS				
		DOCUMENT NUMBER		DATE	COUNTRY	C	LASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE
	2	WO 99/09987		03/04/99	WIPO				
	3	WO 98/43639		10/08/98	WIPO				
	4	WO 96/24353		08/15/96	WIPO		-		

# OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

	5	Hay, "Chronic Obstructive Pulmonary Disease: Emerging Therapies," Current Opinion in Chemical Biology 4:412-419						
		(2000)						
	6	Abraham et al., "Cancer Chemotherapy and Radiation Induced Emesis (CRIE): Current and Future Therapeutic Approaches,"						
		Indian Journal of Pharmacology 32:256-268 (2000)						
	7	Von Sprecher et al., "Neurokinin Antagonists as Potential Therapies for Inflammation and Rheumatoid Arthritis,"						
		<u>Idrugs</u> 1(1):73-91 (1998)						
	8	Rance et al., "Hypertrophy and Increased Gene Expression of Neurons Containing Neurokinin-B and Substance-P Messenger						
		Ribonucleic Acids in the Hypothalami of Postmenopausal Women," Endocrinology 128(5):2239-2247 (1991)						
	9	Casper et al., "Menopausal Flushes: A Neuroendocrine Link with Pulsatile Luteinizing Hormone Secretion,"						
		<u>Science</u> 205:823-825 (1979)						
	10	Norheim et al., "Tachykinins in Carcinoid Tumors: Their Use as a Tumor Marker and Possible Role in the Carcinoid Flush,"						
		Journal of Clinical Endocrinology and Metabolism 63(3):605-612 (1986)						
	11	Conlon et al., "Circulating Tachykinins (Substance P, Neurokinin A, Neuropeptide K) and the Carcinoid Flush,"						
		Scand. J. Gastroenterol. 22: 97-105 (1986)						
	12	Öberg et al., "The Effects of Octreotide on Basal and Stimulated Hormone Levels in Patients with Carcinoid Syndrome,"						
		Journal of Clinical Endocrinology and Metabolism 68(4):796-800 (1989)						
EXAMINER		DATE CONSIDERED						
EXAMINER: Init	ial if cita	tion considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and						
not considered. In	clude cop	by of this form with next communication to applicant.						

								s	heat 2 of 2
U.S. DEPARTMI	FNT OF	COMMERCE	ATTY, DC	OCKET NO.			SERI	IAL NO.	heet 2 of 2
	PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT					i	ì	I of 09/879,390	
				(6-11405-955) NT				01 03/0/3,03	
STATEMENT DI ALIMOANT			APPLICAN Thomas J.	Guttuso, Jr.					
(use several:	(use several sheets if necessary) (PTO-1449)			Guttuso, Jr. ATE			GRO	UP ART UNIT	
(PI				î.TE			Gro	JP AKI UNII	
			Herewith			<del></del>			
				U.S. PATENT	DOCUMENTS				· —
EXAMINER INITIAL		DOCUMENT NUMBER		DATE	NAME	CLA	ıss	SUBCLASS	FILING DATE IF APPRO- PRIATE
	<del> </del>	-							
	<del> </del>		-						
		<del></del>	-			-		+	
	-	<del> </del>	-						
	<del> </del>	<del> </del>				-			
	<del> </del>	-				+	-		
				FOREIGN PATEN	NT DOCUMENTS	<del></del>			
		DOCUM NUME		DATE	COUNTRY	CI	LASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE
		ОТНЕ	R DOCUMEN	NTS (including Aut	thor, Title, Date, Pertinent	Pages, Etc	:.)		
	13	Balks et al., "1	Effect of a Lo	ong-Acting Somatost	tatin Analogue (Octreotide) or	n Circulatir	ng Tach	ykinins and the	
		Pentagastrin-Ir	nduced Carcin	oid Flush," Eur. J.	Clin. Pharmacol. 36:133-13	7 (1989)			
	14	Schaffalitzky d	ie Muckadell	et al., "Flushing and	d Plasma Substance P Concer	ntration Du	ıring Inf	fusion of Synthetic S	Substance
		P in Normal M	fan," Scand. J	J. Gastroenterol. 21:	: 498-502 (1985)				
	_   /								
	_   '								
	!								
EXAMINER					DATE CONSI	DERED			
				ot citation is in conformunication to applicar	ormance with MPEP 609; Dr	raw line thr	ough cit	tation if not in confe	ormance and

# **EXPRESS MAIL CERTIFICATE**

DOCKET NO.:

176/60807 (6-11406-955)

APPLICANT:

Thomas J. Guttuso, Jr.

TITLE:

METHOD OF TREATING SYMPTOMS OF HORMONAL

VARIATION, INCLUDING HOT FLASHES, USING

TACHYKININ RECEPTOR ANTAGONIST

Certificate is attached to the Information Disclosure Statement (1 page) and PTO-1449 (2 page) (in duplicate) with 14 references (not attached) of the above-named application.

EXPRESS MAIL NUMBER:

EV138586781US

DATE OF DEPOSIT:

June 27, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Shawn A. Lockett

(Typed or printed name of person mailing paper or fee)

(Signature of person mailing paper or fee